This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Hematologic malignancies	Janus kinase 2 (JAK2); histone deacetylase (HDAC)	<i>In vitro</i> studies suggest that combining HDAC inhibitors with JAK2 inhibitors could help treat myeloproliferative cancers. In mouse and human hematopoietic progenitor cells expressing the JAK2 mutant JAK2V617F, an HDAC inhibitor plus a JAK2 inhibitor led to greater apoptosis than either compound alone. Next steps could include a clinical trial to test the combination therapy in patients.	Patent and licensing status unavailable	Wang, Y. <i>et al. Blood</i> ; published online Oct. 14, 2009; doi:10.1182/blood-2009-05-222133 Contact: Kapil N. Bhalla, Medical College of Georgia, Augusta, Ga. e-mail: kbhalla@mcg.edu
<i>SciBX</i> 2(45); doi:10.1038/scibx.2009.1660 Published online Nov. 19, 2009				